untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:18:22Z</responseDate>
<request identifier=oai:HAL:hal-01482656v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-01482656v1</identifier>
<datestamp>2018-01-12</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>subject:shs</setSpec>
<setSpec>collection:CNRS</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:UNIV-FCOMTE</setSpec>
<setSpec>collection:UNIV-TLSE3</setSpec>
<setSpec>collection:HCL</setSpec>
<setSpec>collection:AO-ECONOMIE</setSpec>
<setSpec>collection:SANTE_PUB_INSERM</setSpec>
<setSpec>collection:UPMC</setSpec>
<setSpec>collection:CHLS</setSpec>
<setSpec>collection:APHP</setSpec>
<setSpec>collection:IPLESP</setSpec>
<setSpec>collection:SHS</setSpec>
<setSpec>collection:IPLESP-T4</setSpec>
<setSpec>collection:UPMC_POLE_4</setSpec>
<setSpec>collection:CHRONO-ENVIRONNEMENT</setSpec>
<setSpec>collection:UCA-TEST</setSpec>
<setSpec>collection:UNIV-COTEDAZUR</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Comparative risk of failure of ABC/3TC or TDF/FTC based first-line ă regimens in patients with a high viral load</title>
<creator>Flandre, P.</creator>
<creator>Pugliese, P.</creator>
<creator>Allavena, C.</creator>
<creator>Katlama, C.</creator>
<creator>Cotte, L.</creator>
<creator>Cheret, A.</creator>
<creator>Cabié, A.</creator>
<creator>Rey, D.</creator>
<creator>Chirouze, C.</creator>
<creator>Bani-Sadr, F.</creator>
<creator>Cuzin, L.</creator>
<creator>Grp, Dat'AIDS Study</creator>
<contributor>Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP) ; Université Pierre et Marie Curie - Paris 6 (UPMC) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Service d'infectiologie [CHU Nice] ; CHU Nice</contributor>
<contributor>Service des maladies infectieuses et tropicales [CHU Nantes] ; CHU Nantes</contributor>
<contributor>Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière] ; Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Pitié-Salpêtrière [APHP]</contributor>
<contributor>Hospices Civils de Lyon / Centre hospitalier Lyon Sud (HCL) ; Hospices Civils de Lyon</contributor>
<contributor>Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane) ; Université des Antilles et de la Guyane (UAG) - Institut National de la Santé et de la Recherche Médicale (INSERM) - CHU de Pointe-à-Pitre - Centre Hospitalier de Cayenne Andrée Rosemon - CHU de Fort de France</contributor>
<contributor>Les Hôpitaux Universitaires de Strasbourg (HUS)</contributor>
<contributor>Laboratoire Chrono-environnement (LCE) ; Université Bourgogne Franche-Comté (UBFC) - Centre National de la Recherche Scientifique (CNRS) - Université de Franche-Comté (UFC)</contributor>
<contributor>Service des maladies infectieuses et tropicales ; Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon) - Hôpital Saint-Jacques</contributor>
<contributor>Centre Hospitalier Universitaire de Reims (CHU de Reims)</contributor>
<contributor>Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps [Toulouse] ; Université Paul Sabatier - Toulouse 3 (UPS) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<description>International audience</description>
<source>ISSN: 1464-2662</source>
<source>EISSN: 1468-1293</source>
<source>HIV Medicine</source>
<publisher>Wiley</publisher>
<identifier>hal-01482656</identifier>
<identifier>https://hal.archives-ouvertes.fr/hal-01482656</identifier>
<source>https://hal.archives-ouvertes.fr/hal-01482656</source>
<source>HIV Medicine, Wiley, 2016, 17 (5), pp.380-384. 〈10.1111/hiv.12306〉</source>
<identifier>DOI : 10.1111/hiv.12306</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/hiv.12306</relation>
<language>en</language>
<subject lang=en>Quality of Life</subject>
<subject>[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie</subject>
<subject>[SHS.ECO] Humanities and Social Sciences/Economies and finances</subject>
<subject>[SHS.PSY] Humanities and Social Sciences/Psychology</subject>
<subject>[SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>ObjectivesTo compare the efficacy, in current clinical practice, of ă first regimens containing abacavir with lamivudine (ABC/3TC) or ă tenofovir with emtricitabine (TDF/FTC) in patients with baseline viral ă load 100000 HIV-1 RNA copies/mL. ă MethodsUsing a prospective cohort, we selected all patients starting a ă first HIV regimen based either on ABC/3TC or on TDF/FTC. The propensity ă score (PS) method was used to limit the indication bias due to the ă observational nature of the data. Adjusting and weighting methods via PS ă were used to compare the effectiveness of a first regimen containing ă ABC/3TC or TDF/FTC. The primary outcome was treatment failure by month ă 12 (M12). ă ResultsOverall, 2781 patients started an antiretroviral (ARV) regimen ă with ABC/3TC or TDF/FTC each in combination with efavirenz, boosted ă atazanavir or boosted darunavir. Among the 2472 uncensored patients ă before M12, 962 (39%) had a baseline viral load 100000 copies/mL of ă whom 294 were in treatment failure at or before M12. Our analyses showed ă no difference between ABC/3TC and TDF/FTC in the risk of treatment ă failure at M12 in patients starting an ARV regimen with a high viral ă load (100000 copies/mL). ă ConclusionsUsing a large prospectively collected cohort of patients ă seeking care in France, we found no evidence that ABC/3TC based regimens ă led to more failures than TDF/FTC based ones in patients with high ă baseline viral loads.</description>
<date>2016-05</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
